Source: International Congress 2014 – ILDs 3
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. M. Walsh, D. A. Boylan, J. C. Worrell, R. V. Lumsden, R. Kane, M. P. Keane (Dublin, Ireland). The myofibroblast in pulmonary fibrosis displays distinct functional characteristics, depending on its source of origin. Eur Respir J 2014; 44: Suppl. 58, 792

Member's Comments

No comment yet.

Related content which might interest you: Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis? Source: International Congress 2014 – ILDs 1 Year: 2014 MiR-214-3p, a new fibromiR involved in the pathogenesis of idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Analysis of candidate genes of phenotypic expression in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical features of microscopic polyangiitis with usual interstitial pneumonia-like fibrosis in comparison with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014